Comparing HPV vaccine schedules: 2 doses vs 3 doses
Part of Infections clinical trials.
This study compares how well your immune system responds to an HPV vaccine given as either 2 doses or 3 doses in people ages 27–45 who have never had the HPV vaccine. It may help improve HPV prevention strategies and guide the best dose schedule for adults.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are female and between 27 and 45 years old.
- You have never received an HPV vaccine dose before (checked in medical records/HPV registry).
- You can read and speak English or Spanish, and you can be reached by phone during the study.
- You have reliable birth control and plan to continue it through about month 13.
- You are not pregnant now and do not plan to become pregnant or donate eggs for the next 13 months.
- You can stay in the Galveston/Houston area for the next 13 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares the immune response (antibodies) in girls aged 13-14 who have completed either a domestic or imported HPV vaccine. It aims to see if the two vaccines produce similar protection, which might help confirm the effectiveness of the domestic option.
This trial tests a new 15-valent HPV vaccine to see if it is safe and creates a strong immune response. If you are between 9 and 45 years old and have not had an HPV vaccine before, you may be able to join.
This study looks at giving the HPV vaccine (Gardasil 9) to women while they go through Sweden’s routine HPV screening. It helps researchers understand how vaccine use alongside screening affects HPV infection and cervical cancer prevention.
This trial tests an 11-type HPV vaccine to prevent infection from multiple HPV strains. If you enroll, you’ll receive scheduled vaccine doses and have health and gynecologic check-ins to see how well the vaccine works and is tolerated.
This study tests a new HPV vaccine in Chinese women. It looks at whether the vaccine is safe and effective for women who have already had a different HPV vaccine (the bivalent one) and for women who have never had any HPV vaccine.
This study tests whether a single dose of the HPV vaccine is enough to protect against the viruses that cause several cancers. You will have the vaccine and some small tissue samples taken to see how your immune system responds.
Hear when a new Immunization trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.